These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

704 related articles for article (PubMed ID: 31552054)

  • 1. Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice.
    O'Riordan CE; Purvis GSD; Collotta D; Chiazza F; Wissuwa B; Al Zoubi S; Stiehler L; Martin L; Coldewey SM; Collino M; Thiemermann C
    Front Immunol; 2019; 10():2129. PubMed ID: 31552054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. X-Linked Immunodeficient Mice With No Functional Bruton's Tyrosine Kinase Are Protected From Sepsis-Induced Multiple Organ Failure.
    O'Riordan CE; Purvis GSD; Collotta D; Krieg N; Wissuwa B; Sheikh MH; Ferreira Alves G; Mohammad S; Callender LA; Coldewey SM; Collino M; Greaves DR; Thiemermann C
    Front Immunol; 2020; 11():581758. PubMed ID: 33162995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.
    Denzinger V; Busygina K; Jamasbi J; Pekrul I; Spannagl M; Weber C; Lorenz R; Siess W
    Thromb Haemost; 2019 Mar; 119(3):397-406. PubMed ID: 30685871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib.
    Hopper M; Gururaja T; Kinoshita T; Dean JP; Hill RJ; Mongan A
    J Pharmacol Exp Ther; 2020 Mar; 372(3):331-338. PubMed ID: 31871305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
    Kriegsmann K; Kriegsmann M; Witzens-Harig M
    Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linagliptin Attenuates the Cardiac Dysfunction Associated With Experimental Sepsis in Mice With Pre-existing Type 2 Diabetes by Inhibiting NF-κB.
    Al Zoubi S; Chen J; Murphy C; Martin L; Chiazza F; Collotta D; Yaqoob MM; Collino M; Thiemermann C
    Front Immunol; 2018; 9():2996. PubMed ID: 30619349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bruton's tyrosine kinase drives neuroinflammation and anxiogenic behavior in mouse models of stress.
    Ghosh S; Mohammed Z; Singh I
    J Neuroinflammation; 2021 Dec; 18(1):289. PubMed ID: 34895246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD38-mediated Inhibition of Bruton's Tyrosine Kinase in Macrophages Prevents Endotoxemic Lung Injury.
    Farahany J; Tsukasaki Y; Mukhopadhyay A; Mittal M; Nepal S; Tiruppathi C; Malik AB
    Am J Respir Cell Mol Biol; 2022 Feb; 66(2):183-195. PubMed ID: 34706199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrantly expressed Bruton's tyrosine kinase preferentially drives metastatic and stem cell-like phenotypes in neuroblastoma cells.
    Pikatan NW; Liu YL; Bamodu OA; Hsiao M; Hsu WM; Haryana SM; Sutaryo ; Chao TY; Yeh CT
    Cell Oncol (Dordr); 2020 Dec; 43(6):1067-1084. PubMed ID: 32705581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Bruton's TK regulates macrophage NF-κB and NLRP3 inflammasome activation in metabolic inflammation.
    Purvis GSD; Collino M; Aranda-Tavio H; Chiazza F; O'Riordan CE; Zeboudj L; Mohammad S; Collotta D; Verta R; Guisot NES; Bunyard P; Yaqoob MM; Greaves DR; Thiemermann C
    Br J Pharmacol; 2020 Oct; 177(19):4416-4432. PubMed ID: 32608058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Bruton's Tyrosine Kinase Activity Attenuates Hemorrhagic Shock-Induced Multiple Organ Dysfunction in Rats.
    Patel NM; Oliveira FRMB; Ramos HP; Aimaretti E; Alves GF; Coldewey SM; Collino M; Sordi R; Thiemermann C
    Ann Surg; 2023 Mar; 277(3):e624-e633. PubMed ID: 35129479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct Roles for Bruton's Tyrosine Kinase in B Cell Immune Synapse Formation.
    Roman-Garcia S; Merino-Cortes SV; Gardeta SR; de Bruijn MJW; Hendriks RW; Carrasco YR
    Front Immunol; 2018; 9():2027. PubMed ID: 30237801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions.
    Series J; Garcia C; Levade M; Viaud J; Sié P; Ysebaert L; Payrastre B
    Haematologica; 2019 Nov; 104(11):2292-2299. PubMed ID: 30819914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.
    Herman SEM; Montraveta A; Niemann CU; Mora-Jensen H; Gulrajani M; Krantz F; Mantel R; Smith LL; McClanahan F; Harrington BK; Colomer D; Covey T; Byrd JC; Izumi R; Kaptein A; Ulrich R; Johnson AJ; Lannutti BJ; Wiestner A; Woyach JA
    Clin Cancer Res; 2017 Jun; 23(11):2831-2841. PubMed ID: 27903679
    [No Abstract]   [Full Text] [Related]  

  • 15. Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile.
    Barf T; Covey T; Izumi R; van de Kar B; Gulrajani M; van Lith B; van Hoek M; de Zwart E; Mittag D; Demont D; Verkaik S; Krantz F; Pearson PG; Ulrich R; Kaptein A
    J Pharmacol Exp Ther; 2017 Nov; 363(2):240-252. PubMed ID: 28882879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages.
    Ping L; Ding N; Shi Y; Feng L; Li J; Liu Y; Lin Y; Shi C; Wang X; Pan Z; Song Y; Zhu J
    Oncotarget; 2017 Jun; 8(24):39218-39229. PubMed ID: 28424405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
    da Cunha-Bang C; Niemann CU
    Drugs; 2018 Nov; 78(16):1653-1663. PubMed ID: 30390220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
    Zhang Z; Zhang D; Liu Y; Yang D; Ran F; Wang ML; Zhao G
    Arch Pharm (Weinheim); 2018 Jul; 351(7):e1700369. PubMed ID: 29741794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
    Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury.
    Ito M; Shichita T; Okada M; Komine R; Noguchi Y; Yoshimura A; Morita R
    Nat Commun; 2015 Jun; 6():7360. PubMed ID: 26059659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.